Table 2.
Univariate analysis between IVIG-responsive and IVIG-resistant cases.
| Variable | Cut-off point |
IVIG-responsive (n = 259) |
IVIG-resistant (n = 23) |
χ2 | P-value |
|---|---|---|---|---|---|
| Age, months | ≤6.0 | 158 (61.0%) | 16 (69.6%) | 0.655 | 0.418 |
| Gender | Male | 175 (67.6%) | 19 (82.6%) | 2.226 | 0.136 |
| White blood cell, 109/L | ≥14.5 | 129 (49.8%) | 12 (52.2%) | 0.047 | 0.828 |
| Hemoglobin, g/L | ≤100.5 | 122 (47.1%) | 11 (47.8%) | 0.004 | 0.947 |
| NLR | ≥2.69 | 63 (24.3%) | 18 (78.3%) | 30.017 | <0.001 |
| PLR | ≥110.92 | 83 (32.0%) | 16 (69.6%) | 13.052 | <0.001 |
| MPVLR | ≥2.78 | 74 (28.6%) | 19 (82.6%) | 27.907 | <0.001 |
| Alanine transaminase, IU/L | ≥40.0 | 64 (24.7%) | 9 (39.1%) | 2.289 | 0.130 |
| Serum albumin, g/L | ≤30.7 | 17 (6.6%) | 9 (39.1%) | 26.768 | <0.001 |
| Serum sodium, mmol/L | ≤135.2 | 52 (20.1%) | 13 (56.5%) | 15.819 | <0.001 |
IVIG, intravenous immunoglobulin; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; MPVLR, mean platelet volume-to-lymphocyte ratio.